Beta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Rating of “Moderate Buy” from Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $19.70.

BBNX has been the topic of a number of recent research reports. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Bank of America dropped their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Lake Street Capital set a $20.00 target price on Beta Bionics in a research report on Wednesday, February 18th. Weiss Ratings lowered Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus dropped their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd.

Beta Bionics Price Performance

Shares of BBNX opened at $14.53 on Friday. The stock’s 50-day moving average is $11.31 and its two-hundred day moving average is $16.70. The stock has a market cap of $647.46 million, a PE ratio of -9.62 and a beta of 3.40. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. On average, research analysts anticipate that Beta Bionics will post -2.22 earnings per share for the current year.

Insider Buying and Selling at Beta Bionics

In other news, Director Christy Jones sold 2,811 shares of Beta Bionics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00. Following the sale, the director directly owned 27,400 shares of the company’s stock, valued at approximately $383,600. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,676 shares of Beta Bionics stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $84,184.36. Following the sale, the chief financial officer directly owned 166,053 shares in the company, valued at approximately $2,093,928.33. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 27,687 shares of company stock valued at $343,586. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

A number of hedge funds and other institutional investors have recently modified their holdings of BBNX. Vanguard Group Inc. increased its position in shares of Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Beta Bionics in the fourth quarter valued at about $40,437,000. Eversept Partners LP increased its holdings in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares during the last quarter. 12 West Capital Management LP bought a new stake in Beta Bionics in the fourth quarter valued at about $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in Beta Bionics in the first quarter valued at about $5,518,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.